March 17, 2008 8:00AM Eastern Daylight Time
AvivoClin Clinical Services Announces Upcoming Expansion
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) is pleased to announce the future expansion of its clinical pharmacology research facility, AvivoClin Clinical Services, located in Daytona Beach, Fla. Azopharma introduced AvivoClin Clinical Services (formerly Coastal Medical Research) as a member of the Azopharma Product Development Group in January of this year. The expansion of the facility is scheduled for completion in late August 2008.
The expanded facility will include an additional 5,000 square feet bringing the new facility to a total of 20,000 square feet. The patient bed capacity will also increase from 48 to 100 beds. According to Phil Meeks, Azopharma Chief Executive Officer, “The expansion of the AvivoClin facility allows us to grow our clinical services to better meet the growing needs of our clients. Through AvivoClin, Azopharma Product Development Group can support numerous clinical studies simultaneously resulting in a higher level of service to our clients.”
AvivoClin Clinical Services plans for expansion include:
· Increase square footage from 15,000 to 20,000 square feet
· Additional bed capacity from 48 to 100 beds
· Larger patient recreation and dining space
· Expanded shower and restroom facilities
· Expanded lab facilities, exam rooms and telemetry monitoring capabilities
· Additional certified staff and recruitment specialists
|
The expansion of AvivoClin Clinical Services combined with Azopharma’s latest acquisition of Analytical Development Corporation, now ADMEquant Bioanalytical Services, allows Azopharma Product Development Group to provide comprehensive clinical pharmacology services which includes both clinical and analytical services. The expansion also further enhances Azopharma’s ability to provide total product development services for pharmaceuticals and medical devices. Mr. Meeks continues, “Azopharma Product Development Group is only one of a few organizations in the U.S. that are capable of developing a full spectrum of dosage forms from discovery through commercialization. By bringing together the best scientists in the field, state-of-the-art facilities and our focus on quality means that we can provide our partners a winning combination in total product development.”
Azopharma Product Development Group Includes:
- Azopharma Contract Pharmaceutical Services - Integrated product development and CTM manufacturing for all dosage forms.
- ApiCross Drug Delivery Technologies - Proprietary drug delivery platforms to solve difficult molecular challenges.
- Cyanta Analytical Laboratories - Analytical chemistry and inhalation services from development to quality control testing.
- AniClin Preclinical Services - Preclinical services in support of early product development.
- IQsynthesis - Synthetic chemistry services from discovery to clinical API supplies including large scale API synthesis.
- AvivoClin Clinical Services - Human clinical pharmacology services for Phase I/II/III clinical trials.
- ADMEquant Bioanalytical Services - Bioanalytical research analysis of pharmaceutical compounds in all matrices.
About Azopharma
Azopharma Product Development Group is FDA registered, DEA approved and client audited on a regular basis. Azopharma’s mission is to help our customers turn Ideas Into Cures™. In product development, it comes down to the right people, their commitment and application of experience. Partnering with Azopharma provides customers with the confidence of assured success. We welcome visits to our facility in Hollywood, FL as well as our other sites to conduct audits or meet with our pharmaceutical scientists to outline a study that meets your specific needs. Contact us at development@azopharma.com or 954-433-7480.
Contact
Phil Meeks, CEO
Azopharma Product Development Group
2 Oakwood Boulevard, Suite 170
Hollywood, FL 33020
Phone: 954-433-7480
www.azopdogroup.com